|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals (BRL) and a provider of generic and proprietary pharmaceuticals. |
|---|---|
| Transferring Party | FEI Womens' Health, LLC, a provider of the IUD devices. |
| Sector | Medical Devices |
| Date | November 10, 2005 |
| Analysis Expands Duramed's presence and commitment beyond oral contraception and into the non-hormone contraceptive marketplace. FEI owns the New Drug Application (NDA) for the ParaGard® T 380A (Intrauterine Copper Contraceptive) IUD which is the only contraceptive approved for 10 years of continuous use and is more than 99% effective at preventing pregnancy. Deal value: $281.5 million. FEI's 50-person sales force will be integrated with Duramed's, making a total of more than 100 salespersons. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |